Claritev (CTEV) Q4 2025 earnings review
The Turn is Real, But the 'Way Up' Looks Steep
Claritev successfully stabilized its core business in 2025, culminating in a strong Q4 with revenue up 6.2% YoY. Management's narrative that 2025 was the 'Year of the Turn' is supported by sequential improvements and a return to positive top-line growth. However, the initial outlook for 2026—dubbed 'The Way Up'—tempers excitement. FY26 revenue guidance implies just ~2.5% YoY growth, a sharp deceleration from the second half of 2025. Furthermore, while the company generated $36.4M of Free Cash Flow in Q4, the crushing weight of a $4.56B debt load ($392M in annual interest expense) leaves little room for error. The newly announced $75M share repurchase program is confusing given the company's own projection of generating a maximum of $10M in FCF next year.
🐂 Bull Case
After quarters of managing client attrition, Claritev renewed all top 10 clients in 2025. Q4 processed claim charges hit $47.2B (up sequentially), identifying $6.4B in potential medical cost savings.
Despite a massive transformation effort (Vision 2030), Adjusted EBITDA margins have held steady above 61%. FY25 Adjusted EBITDA grew 4.5% YoY, outpacing revenue growth.
🐻 Bear Case
The company holds $4.56B in long-term debt, which generated $392M in interest expense in 2025. This effectively erases all operating leverage, keeping Free Cash Flow deeply constrained.
Management boasts of entering the growth phase, yet FY26 revenue guidance of $980M-$1B implies growth of just 1.5% to 3.6%. A known non-recurring revenue benefit of $15-$18M in 2025 creates a difficult comparison for the upcoming year.
⚖️ Verdict: ⚪
Neutral. Management deserves credit for stopping the bleeding and successfully executing the Vision 2030 technical and operational re-alignment. However, until the debt is meaningfully reduced, the equity remains a highly levered option on modest top-line growth.
Key Themes
The Math Behind the Buyback Doesn't Work
The Board approved a $75M, five-year share repurchase program (capped at $20M per year). Yet, management's own FY26 Free Cash Flow guidance is just $0 to $10M. With unrestricted cash sitting at only $16.8M, executing this buyback would likely require drawing on the revolving credit facility—directly contradicting the company's stated goal of opportunistic debt reduction.
The 'Way Up' Narrative Contradicts the Guidance
CEO Travis Dalton claims 2026 is 'The Way Up,' but the numbers suggest a deceleration. Q3 and Q4 2025 revenue grew 6.7% and 6.2%, respectively. The FY26 guidance midpoint of $990M implies just ~2.5% YoY growth. This slowdown is largely due to a $15-$18M non-recurring P&C contract booked in 2025 that management previously acknowledged would be a headwind. The narrative is aggressive; the guidance is defensive.
Healthcare Inflation as a Macro Tailwind
The broader macroeconomic environment is currently working in Claritev's favor. Management noted in prior quarters that elevated healthcare inflation (running at 6-9%) combined with stable out-of-network claims volumes provides a direct boost. Because Claritev operates largely on a Percentage of Savings (PSAV) model, higher-dollar medical claims inherently increase the absolute dollar value of the savings they capture.
Expansion Beyond the Core Payer Market
A central pillar of the Vision 2030 strategy is expanding the Total Addressable Market. The company is actively moving beyond its traditional Payer/TPA base into new verticals: Broker/Employer, Provider, and Government. Bookings momentum is solid, with over 100 deals signed in the Broker space and early traction with products like PlanOptix and CompleteVue.
Technology Modernization & Oracle Partnership
The migration of Claritev's foundational technology to Oracle Cloud Infrastructure (OCI) is unlocking operational efficiencies. The partnership goes beyond hosting; Claritev is embedding its solutions directly into Oracle's HCM products, creating a powerful new enterprise sales channel. Additionally, the integration of new AI solutions is aimed at analyzing data faster and improving the 'percentage of actionable claims' yield.
Structural Issues in the No Surprises Act (NSA) Market
Despite investing heavily in analytics for the No Surprises Act dispute resolution process, management previously admitted a structural market flaw: providers still win 80% of disputes. While Claritev has lowered its operational unit cost to service an Independent Dispute Resolution (IDR) claim by 70%, the low win rate fundamentally caps the upside of this regulatory-driven business segment.
Other KPIs
Stable. The company delivered $151.3M in Adjusted EBITDA in Q4 on $246.6M in revenue. For the full year, Adjusted EBITDA grew 4.5% YoY to $602.6M, slightly outpacing the 3.7% revenue growth. The ability to maintain 60%+ margins while funding the Vision 2030 transformation is a key bright spot.
Accelerating. Interest expense rose from $326.3M in FY24 to $392.0M in FY25. This line item consumes roughly two-thirds of the company's Adjusted EBITDA and highlights why deleveraging must remain the absolute priority over share repurchases.
Guidance
Decelerating. The midpoint of $990M implies a 2.5% YoY growth rate compared to FY25's $965.4M. This represents a step down from the ~6% growth achieved in the second half of 2025, reflecting the roll-off of non-recurring 2025 contracts.
Decelerating. The midpoint of $610M implies a 1.2% YoY growth rate. The implied margin at the midpoint of revenue and EBITDA is ~61.6%, representing a slight compression from the 62.4% margin achieved for the full year 2025.
Reversing. Turning positive after generating $(12.3)M in FY25. The positive inflection is encouraging, but the absolute dollar amount remains razor-thin for a company with a multi-billion dollar enterprise value.
Stable. In line with the $129.6M spent in FY25 plus capitalized software costs. This reflects the ongoing heavy investment required to complete the Vision 2030 technology migration.
Key Questions
Capital Allocation Disconnect
With FY26 Free Cash Flow guided to a maximum of $10 million and your stated priority of 'opportunistic debt reduction,' how do you mathematically justify authorizing a $20M per year share repurchase program without taking on more leverage?
Growth Cadence and the 'Way Up'
You've labeled 2026 as 'The Way Up,' yet the revenue guidance midpoint implies a severe deceleration from Q4's 6.2% growth down to 2.5%. Can you walk us through the quarter-by-quarter cadence for 2026 and quantify the exact impact of the non-recurring 2025 contracts?
Margin Compression in Guidance
The FY26 guidance implies Adjusted EBITDA margins of 61.6%, a step down from FY25's 62.4%. Is this margin compression a result of planned price concessions, wage inflation, or accelerated OpEx investments to support the new vertical expansions?